Bernal, T
Martínez-Camblor, P
Sánchez-García, J
de Paz, R
Luño, E
Nomdedeu, B
Ardanaz, M T
Pedro, C
Amigo, M L
Xicoy, B
del Cañizo, C
Tormo, M
Bargay, J
Valcárcel, D
Brunet, S
Benlloch, L
Sanz, G
,
Article History
Received: 3 March 2015
Revised: 21 April 2015
Accepted: 24 April 2015
First Online: 6 May 2015
Competing interests
: TB has served as advisory board member and consultant for Celgene. DV is part of the speaker bureau of Celgene, Amgen, GSK, Novartis, MSD and astellas, and member of advisory boards for Celgene, Amgen, GSK and Pfizer. GS has received honoraria and research funding from Celgene, Novartis and Amgen, and is on the advisory committee for Amgen, Böehringer-Ingelheim, Celgene, Merck-Sharp and Dohme and Novartis. The Spanish Group on Myelodysplastic Syndromes is sponsored by Celgene and Novartis. The remaining authors declare no conflict of interest.